For patients with multiple myeloma, there are a variety of agents now available that are being investigated in different approaches or sequences, according to Adam Waxman, MD.
, Waxman, internist at the University of Pennsylvania, discussed emerging regimens for patients with multiple myeloma.
OncLive: Please provide an overview of your lecture.
We discussed early relapse therapies, the many new treatments, and important randomized phase III trials for patients with multiple myeloma. We focused on second- generation proteasome inhibitors, such as carfilzomib and ixazomib, as well as the monoclonal antibodies elotuzumab and daratumumab. We looked at the randomized data for patients who are receiving somewhere between their first- and third-line of therapy after initial therapy.
[With] triplets versus doublets in therapy for multiple myeloma, we are finding that we tend to see higher progression-free survival rates, and, in some cases, [improved] overall survival when patients are in their early relapse. Of course, with important attention being placed on different drug toxicities, it is important to be careful when selecting patients who will receive triplet therapy.
What are some factors to consider when sequencing therapies for patients who relapse?
This is part of the art of treating this disease because there are no multistage randomized trials where a patient is randomized to different sequences.
... to read the full story